3 terminated, 2 active not recruiting. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 2, Terminated 1 |
| Phase 2 | 3 | Terminated 2, Active not recruiting 1 |
Follow SOTIO Biotech AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer SOT201 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Active not recruiting | SOTIO Biotech AG | 40 | 2024-05-01 | 2026-10-14 |
| A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer Nanrilkefusp alfa, Cetuximab - Colorectal Cancer | Phase 2 | Terminated | SOTIO Biotech AG | 16 | 2022-12-22 | 2025-07-24 |
| BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors CAR-GPC3 T Cells - Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung | Phase 1 / Phase 2 | Active not recruiting | Sotio Biotech Inc. | 7 | 2022-10-26 | 2025-12-05 |
| A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors Nanrilkefusp Alfa, Pembrolizumab - Non-Small Cell Lung Cancer, Colorectal Cancer | Phase 2 | Terminated | SOTIO Biotech AG | 166 | 2022-06-21 | 2025-11-17 |
| Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors Nanrilkefusp alfa, Pembrolizumab - Thyroid Cancer, Renal Cell Carcinoma | Phase 1 | Terminated | SOTIO Biotech AG | 115 | 2019-06-13 | 2026-03-27 |
Carcinoma, Hepatocellular (3) · Carcinoma, Merkel Cell (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Ovarian Neoplasms (2) · Anus Neoplasms (1) · Biliary Tract Neoplasms (1) · Carcinoma, Renal Cell (1) · Liposarcoma, Myxoid (1) · Melanoma (1) · Mesothelioma (1) · Neoplasm Metastasis (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1)
pembrolizumab (2) · Cetuximab (1)
France (4) · Spain (4) · United States (4) · Belgium (3) · Czechia (3) · Georgia (1) · Hungary (1) · Italy (1) · Poland (1) · United Kingdom (1)
Aung Naing, MD, FCAP (1) · Pauline Duhard, Pharm.D. (1) · Stephane Champiat, Dr. (1)
2018 (1), 2023 (1)